Compare MAMA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAMA | VYGR |
|---|---|---|
| Founded | 2010 | 2013 |
| Country | United States | United States |
| Employees | N/A | 172 |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.8M | 222.4M |
| IPO Year | N/A | 2015 |
| Metric | MAMA | VYGR |
|---|---|---|
| Price | $14.81 | $4.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $16.80 | ★ $17.00 |
| AVG Volume (30 Days) | 306.1K | ★ 574.7K |
| Earning Date | 12-08-2025 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.91 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $151,312,000.00 | $31,316,000.00 |
| Revenue This Year | $39.64 | N/A |
| Revenue Next Year | $28.85 | $71.78 |
| P/E Ratio | $123.45 | ★ N/A |
| Revenue Growth | ★ 29.92 | N/A |
| 52 Week Low | $5.50 | $2.65 |
| 52 Week High | $15.30 | $5.96 |
| Indicator | MAMA | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 50.78 |
| Support Level | $12.73 | $3.56 |
| Resistance Level | $15.30 | $4.22 |
| Average True Range (ATR) | 0.58 | 0.25 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 81.66 | 71.32 |
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.